Q3 2024 Holdings
Filed 2024-11-14 | 64 holdings | $2.9B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc(APLS) | COM | 03753U106 | $342.9M | 11,890,843 | 11.7% |
| Anaptysbio Inc(ANAB) | COM | 032724106 | $261.1M | 7,794,996 | 8.9% |
| Crinetics Pharmaceuticals in(CRNX) | COM | 22663K107 | $219.1M | 4,288,120 | 7.5% |
| Prothena Corp PLC(PRTA) | SHS | G72800108 | $193.8M | 11,584,280 | 6.6% |
| Jazz Pharmaceuticals PLC(JAZZ) | SHS USD | G50871105 | $190.1M | 1,706,469 | 6.5% |
| Zymeworks Inc(ZYME) | COM | 98985Y108 | $168.6M | 13,437,473 | 5.8% |
| Arvinas Inc(ARVN) | COM | 04335A105 | $165.7M | 6,726,491 | 5.7% |
| Kura Oncology Inc(KURA) | COM | 50127T109 | $113.5M | 5,806,871 | 3.9% |
| Xencor Inc(XNCR) | COM | 98401F105 | $107.2M | 5,330,416 | 3.7% |
| Tango Therapeutics Inc(TNGX) | COM | 87583X109 | $102.6M | 13,330,736 | 3.5% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $66.8M | 1,469,818 | 2.3% |
| Crispr Therapeutics AG(CRSP) | NAMEN AKT | H17182108 | $65.3M | 1,389,276 | 2.2% |
| Immunome Inc(IMNM) | COM | 45257U108 | $56.7M | 3,879,415 | 1.9% |
| Neurogene Inc(NGNE) | COM | 64135M105 | $53.3M | 1,271,342 | 1.8% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $51.5M | 3,223,851 | 1.8% |
| Viridian Therapeutics Inc(VRDN) | COM | 92790C104 | $44.6M | 1,958,847 | 1.5% |
| Nuvation BIO Inc(NUVB) | COM CL A | 67080N101 | $44.0M | 19,209,643 | 1.5% |
| Third Harmonic BIO Inc(THRD) | COM | 88427A107 | $43.1M | 3,182,444 | 1.5% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $40.3M | 352,464 | 1.4% |
| Mersana Therapeutics Inc | COM | 59045L106 | $36.6M | 19,364,688 | 1.3% |
| Oric Pharmaceuticals Inc(ORIC) | COM | 68622P109 | $35.0M | 3,418,068 | 1.2% |
| Avidity Biosciences Inc(RNA) | COM | 05370A108 | $34.8M | 757,576 | 1.2% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $33.4M | 1,250,385 | 1.1% |
| MBX Biosciences Inc(MBX) | COM ADDED | 55287L101 | $30.5M | 1,175,809 | 1.0% |
| Neumora Therapeutics Inc.(NMRA) | COM | 640979100 | $27.4M | 2,071,450 | 0.9% |
| Cargo Therapeutics Inc(CRGX) | COM | 14179K101 | $27.1M | 1,470,000 | 0.9% |
| Adaptimmune Therapeutics PLC(ADAPY) | SPONDS ADR | 00653A107 | $26.0M | 27,404,070 | 0.9% |
| Tectonic Therapeutic Inc(TECX) | COM | 878972108 | $25.7M | 849,143 | 0.9% |
| Tscan Therapeutics Inc(TCRX) | COM | 89854M101 | $24.9M | 5,000,000 | 0.9% |
| Voyager Therapeutics Inc(VYGR) | COM | 92915B106 | $22.9M | 3,917,546 | 0.8% |
| Celldex Therapeutics Inc New(CLDX) | COM NEW | 15117B202 | $22.1M | 650,000 | 0.8% |
| Bicycle Therapeutics PLC(BCYC) | SPONSORED ADS | 088786108 | $20.6M | 910,000 | 0.7% |
| Ionis Pharmaceuticals Inc(IONS) | COM | 462222100 | $20.0M | 500,000 | 0.7% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $20.0M | 555,644 | 0.7% |
| Atea Pharmaceuticals Inc(AVIR) | COM | 04683R106 | $18.2M | 5,441,896 | 0.6% |
| Relay Therapeutics Inc(RLAY) | COM | 75943R102 | $17.7M | 2,500,000 | 0.6% |
| Pharvaris N V(PHVS) | COM | N69605108 | $16.7M | 900,000 | 0.6% |
| Iteos Therapeutics Inc(5E7) | COM | 46565G104 | $16.4M | 1,608,616 | 0.6% |
| Madrigal Pharmaceuticals Inc(MDGL) | COM | 558868105 | $15.9M | 75,000 | 0.5% |
| DAY One Biopharmaceuticals I(DAWN) | COM | 23954D109 | $12.0M | 862,068 | 0.4% |
| Keros Therapeutics Inc(KROS) | COM | 492327101 | $10.9M | 187,500 | 0.4% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $9.3M | 850,341 | 0.3% |
| Allovir Inc | COM | 019818103 | $9.1M | 11,294,585 | 0.3% |
| Lenz Therapeutics Inc(LENZ) | COM | 52635N103 | $8.2M | 346,772 | 0.3% |
| Verve Therapeutics Inc | COM | 92539P101 | $6.1M | 1,250,000 | 0.2% |
| Generation BIO Co(GBIOGBX) | COM | 37148K100 | $5.1M | 2,046,867 | 0.2% |
| Galapagos NV(GLPG) | SPON ADR | 36315X101 | $4.5M | 155,006 | 0.2% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $4.3M | 170,172 | 0.1% |
| Atara Biotherapeutics Inc(ATRA) | COM NEW | 046513206 | $3.8M | 468,938 | 0.1% |
| Aadi Bioscience Inc(WHWK) | COM | 00032Q104 | $3.8M | 1,845,253 | 0.1% |